Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Daniel A, Nikcevich"'
Autor:
Fang-Shu Ou, Tsung Teh Wu, Brenda Ginos, Harry H. Yoon, Timothy F. Drevyanko, Steven R. Alberts, Maged F. Khalil, Gamini S. Soori, Robert J. Behrens, Dennis A. Wigle, Stephen J. Ko, Daniel A. Nikcevich, Robert C. Miller, George P. Kim, Qian Shi, James L. Leenstra, Patrick J. Peller, Robert P. Sticca, Erica N. Heying, Bassam I. Mattar
Publikováno v:
Eur J Cancer
Aim report primary results from the first multicentre randomised trial evaluating induction chemotherapy prior to trimodality therapy in patients with oesophageal or gastro-oesophageal junction adenocarcinoma. Notably, recent data from a single-insti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ce13a9057acb2bfff58f618fe48d947
https://doi.org/10.1016/j.ejca.2021.03.025
https://doi.org/10.1016/j.ejca.2021.03.025
Autor:
Betsy LaPlant, Dennis F. Moore, Nassim H. Nabbout, Axel Grothey, Kendrith M. Rowland, Thomas E. Witzig, Daniel A. Nikcevich, Patrick B. Johnston, Levi Pederson, Paul J. Kurtin
Publikováno v:
American Journal of Hematology. 92:1004-1010
Patients with relapsed aggressive non-Hodgkin lymphoma (NHL) are often treated with platinum-based chemoimmunotherapy regimens in preparation for autologous stem cell transplant. We sought to reduce toxicity and maintain efficacy by using oxaliplatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29a520aa6af237e198c6b7c713ef151f
https://doi.org/10.1002/ajh.24824
https://doi.org/10.1002/ajh.24824
Autor:
Diane F. Jelinek, Jeremy T. Larsen, Charla R. Secreto, Jose F. Leis, Thomas M. Habermann, Deborah J. Bowen, Betsy LaPlant, Connie Lesnick, T. G. Call, Charles Erlichman, Curtis A. Hanson, Tait D. Shanafelt, Craig B. Reeder, Neil E. Kay, Daniel A. Nikcevich, Renee C. Tschumper, Justin C. Boysen, Adam Pettinger, Wei Ding, Michael S. Conte
Publikováno v:
American Journal of Hematology. 92:759-763
Akt is a downstream target of B cell receptor signaling and is a central regulator of CLL cell survival. We aim to investigate the safety and efficacy of the Akt inhibitor MK-2206 in combination with bendamustine and rituximab (BR) in relapsed and/or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8d3dead857f310ec685f4b8d177445b
https://doi.org/10.1002/ajh.24762
https://doi.org/10.1002/ajh.24762
Autor:
Jose F. Leis, Adam Pettinger, Neil E. Kay, Timothy G. Call, Tait D. Shanafelt, Connie Lesnick, Curtis A. Hanson, Paolo Strati, Daniel A. Nikcevich, Betsy LaPlant
Publikováno v:
Oncotarget
// Neil E. Kay 1 , Paolo Strati 1 , Betsy R. LaPlant 1 , Jose F. Leis 2 , Daniel Nikcevich 3 , Timothy G. Call 1 , Adam M. Pettinger 1 , Connie E. Lesnick 1 , Curtis A. Hanson 1 and Tait D. Shanafelt 1 1 Mayo Clinic College of Medicine, Rochester, MN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e56056ae4586b6294428d2e1483f1117
https://doi.org/10.18632/oncotarget.13412
https://doi.org/10.18632/oncotarget.13412
Autor:
Betsy LaPlant, B. S. Lair, Thomas E. Witzig, Paul A. S. Fishkin, Matthew T. Drake, David J. Inwards, Paul J. Kurtin, Donald B. Wender, Daniel A. Nikcevich
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 30(2)
Abstract 3661 Objective: We conducted this trial to determine the maximum tolerated dose (MTD) and schedule of temsirolimus added to an established regimen comprised of rituximab and cladribine for the initial treatment of mantle cell lymphoma and to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d2ea982d752b08a624ba3a2be7fdb80
https://pubmed.ncbi.nlm.nih.gov/25057177
https://pubmed.ncbi.nlm.nih.gov/25057177
Autor:
Jacob B. Allred, Edith A. Perez, Robert J. Behrens, Amylou C. Dueck, Timothy J. Hobday, Wilma L. Lingle, Tom R. Fitch, Daniel A. Nikcevich, Donald W. Northfelt, Kendrith M. Rowland, Kostandinos Sideras
Publikováno v:
Clinical Breast Cancer. 12:387-391
Angiogenesis is an established target for the treatment of MBC. Aflibercept (VEGF-Trap) is a humanized fusion protein, which binds VEGF-A, VEGF-B, and PIGF-1 and -2.A 2-stage phase II study with primary end points of confirmed tumor response and 6-mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::099aa7d1857b5acf2913bdb3d70725a2
https://doi.org/10.1016/j.clbc.2012.09.007
https://doi.org/10.1016/j.clbc.2012.09.007
Autor:
Patricia A. Koenig, Charles Erlichman, Thomas E. Witzig, Steven C. Ziesmer, Grzegorz S. Nowakowski, Garth D. Nelson, Daniel A. Nikcevich, Paul J. Kurtin, Hui Tang, Stephen M. Ansell, Peter T. Silberstein, Zhi-Zhang Yang, Deanna M. Grote
Publikováno v:
Leukemia
Follicular lymphoma exhibits intratumoral infiltration by non-malignant T lymphocytes, including CD4+CD25+ regulatory T (T(reg)) cells. We combined denileukin diftitox with rituximab in previously untreated, advanced-stage follicular lymphoma patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf1684dc0776ebc948267d2261080daa
http://europepmc.org/articles/PMC3266999
http://europepmc.org/articles/PMC3266999
Autor:
Patrick B. Johnston, Grzegorz S. Nowakowski, Sergei Syrbu, David J. Inwards, Paul J. Kurtin, James R. Cerhan, Luis F. Porrata, Joseph P. Colgan, William R. Macon, Svetomir N. Markovic, Brian K. Link, Thomas M. Habermann, Ivana N. Micallef, Stephen M. Ansell, Matthew J. Maurer, Daniel A. Nikcevich, Jerry A. Katzmann, Mamta Gupta, Carrie A. Thompson, Thomas E. Witzig
Publikováno v:
Journal of Clinical Oncology. 29:1620-1626
Purpose The serum free light chain (FLC) assay quantitates free kappa (κ) and free lambda (λ) immunoglobulin light chains. This assay has prognostic value in plasma cell proliferative disorders. There are limited data on serum FLC in B-cell maligna
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e86efd3940fc10b80dd57e3e87fb8805
https://doi.org/10.1200/jco.2010.29.4413
https://doi.org/10.1200/jco.2010.29.4413
Autor:
R. F. Luyun, Howard L. Ritter, Phuong L. Nguyen, Charles L. Loprinzi, Bassam I. Mattar, Daniel A. Nikcevich, Amylou C. Dueck, Aminah Jatoi
Publikováno v:
Lung Cancer. 68:234-239
This study tested whether infliximab, a chimeric IgG1kappa monoclonal antibody that blocks tumor necrosis factor (TNF) alpha, improves/stabilizes weight loss in elderly and/or poor performance status patients with metastatic non-small cell lung cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad047109b67e3692723e86d9618e7e5a
https://doi.org/10.1016/j.lungcan.2009.06.020
https://doi.org/10.1016/j.lungcan.2009.06.020
Autor:
Kurt A. Jaeckle, Caterina Giannini, Evanthia Galanis, Jan C. Buckner, Julie E. Hammack, Karla V. Ballman, Donald B. Wender, Joon H. Uhm, Paul D. Brown, Robert M. Arusell, Roscoe F. Morton, Paula J. Schomberg, Renee M. McGovern, Stephanie L. Safgren, Joel M. Reid, Daniel A. Nikcevich, Matthew M. Ames
Publikováno v:
Journal of Neuro-Oncology. 99:73-80
Irinotecan has radiosensitizing effects and shows synergism with nitrosoureas. We performed a Phase II study of RT and irinotecan, followed by BCNU plus irinotecan in newly-diagnosed GBM. The MTD for patients receiving enzyme-inducing anticonvulsants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2a36754aa942deb43b8de62def0d23f
https://doi.org/10.1007/s11060-009-0103-2
https://doi.org/10.1007/s11060-009-0103-2